Phathom Pharmaceuticals, Inc. (PHAT) fair value analysis
Nasdaq · Updated 2026-10-19
PHAT price how computed
Valuation status
Awaiting full valuationPHAT's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once PHAT's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $6.92
- Sector
- Healthcare
- 12-month range
- $6.70–$18.08
- Market cap
- $560M
- From 52-week high
- -61.7%
- Shares outstanding
- 80.9M
- Rank in Healthcare by quality score
- #206 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes medicines to treat gastrointestinal conditions. The company operates in the United States and other markets, focusing on bringing novel therapeutic options to patients with disorders of the digestive system.
PHAT currently ranks #206 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $560M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $240M
- Net margin
- -41.3%
- EPS (TTM)
- $-0.57
- Gross margin
- 79.7%
- Debt / equity
- 0.00
- Shares outstanding
- 80.9M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 40 · neutral
- 50-day average
- $8.16
- 200-day average
- $10.91
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-10-29
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+46.7%)
2026-03 ▲ beat (+53.8%)
2025-12 ▲ beat (+20.0%)
2025-09 ▲ beat (+63.4%)
2025-06 ▼ miss (-4.7%)
2025-03 ▼ miss (-0.4%)
2024-12 ▲ beat (+2.8%)
2024-09 ▲ beat (+28.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 2 hold · 0 sell (12 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $20.1
- Target vs last price
- +190.5%
What our data shows for PHAT
- Shares are trading in the lower third of their 12-month price range of $6.70–$18.08.
- The 14-day relative strength index sits at a neutral 40.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- PHAT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent PHAT news
TickrTrends' derived news-sentiment signal for PHAT is currently leaning positive, computed from recent coverage.
- Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA (manilatimes.net, 2026-10-23)
- Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting (manilatimes.net, 2026-10-08)
- PHAT Initiates Coverage On Leerink Partners -- Rating Set to Market Perform (gurufocus.com, 2026-09-09)
TickrTrends take: Leerink Partners has initiated coverage of PHAT with a Market Perform rating, which represents a neutral stance on the stock's near-term direction. Given that TickrTrends' current valuation assessment for PHAT remains awaiting full valuation, this analyst initiation provides additional perspective on how the market may be pricing the Healthcare company relative to its fundamentals. Valuation-focused investors should monitor whether subsequent analyst coverage and price targets help establish clearer valuation benchmarks for PHAT as more research accumulates.
More PHAT news
- Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT) (seekingalpha.com, 2026-09-09)
What people are saying
Follow the PHAT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is PHAT stock undervalued?
PHAT's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is PHAT's TickrTrends verdict?
PHAT is currently marked 'Awaiting full valuation' - a verdict publishes automatically once PHAT's own trailing P/E history validates under our standards.
How does PHAT compare to other Healthcare stocks?
PHAT ranks #206 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is PHAT overbought or oversold?
PHAT's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does PHAT report earnings next?
PHAT's next earnings report is scheduled for 2026-10-29, per the published earnings calendar.
Does PHAT usually beat earnings estimates?
Over its last 8 reported quarters PHAT beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PHAT?
Of 12 analysts covering PHAT, 10 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $20.1 (+190.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.